/ml) were then cultured in RPMI-1640 containing 15% (v/v) FBS (fetal bovine serum, HyClone Laboratory, USA). b The leukemia cells were seeded into 96-well plates, with a density of 1 × 10 5 cells per well. The cells were cultured for 10 days with or without 100 ng/ml M-CSF (Cetus Corporation, Emeryville, CA, USA), then 10 l MTT (Sigma, 5 mg/ml) was added to each well; 4 h later, an equal volume of 10% SDS-10 mM HCl was added to dissolve the blue crystals of formazan. Then the samples were measured at OD 570nm by an ELISA reader (Dynatech Laboratories, USA). All experiments were performed in triplicate, and data are expressed as means ± s.d. Data obtained from cultures with 100 ng/ml were set against those without M-CSF. M-CSF is believed to promote the survival and proliferation of leukemia cells if the ratio is above 2.0. expression of XIAP induced by M-CSF. As expected, treatment of day 10 M-respond cells with 25 g/ml CAPE, which was dissolved in dimethyl sulfoxide (DMSO), resulted in a marked decrease in the level of XIAP after the removal of M-CSF, while treatment with equal volume of DMSO had no significant effect on the level of XIAP. The decrease in XIAP induced by CAPE treatment was accompanied by cell death through an apoptotic mechanism ( Figure 2 ). Furthermore, significant XIAP down-regulation occurred as early as 8 h after CAPE treatment in M-CSF-induced bone marrow-derived macrophages, while obvious cell death appeared much later (samples from normal people, our unpublished data). Therefore, the decreased expression of XIAP did not seem to be a nonspecific consequence of the death process. Since XIAP is the most potent mammalian IAP and is significantly up-regulated in M-respond cells, the fact that CAPE induced XIAP down-regulation and apoptosis of M-respond cells suggests that XIAP might play a role in M-CSF-mediated survival of myeloid leukemia cells. However, as NF-B may regulate the expression of a large number of genes, including IAPs other than XIAP, 3 further demonstration is needed to prove that the decreased expression of XIAP resulted in the cell death induced by CAPE. Also, XIAP is probably not the only parameter that accounts for the ability of leukemia cells to survive in culture conditions; it may co-operate with other antiapoptotic proteins. Bcl-2 may be such a component since it was also up-regulated by M-CSF in M-respond cells. vated after exposure to DNA damaging agents. 1 A hallmark of many tumor cells is that the p53 gene is mutated and expressed at greatly elevated levels. We have been interested in determining the cause of lack of expression of the p53 gene in cell lines derived from myeloid leukemias. Although numerous tumor types express elevated levels of mutant p53, it has been demonstrated that some astrocytomas, 2 a high proportion of breast cancers 3 and many human myeloid leukemias do not express detectable levels of p53 mRNA. 4 The mechanism responsible for the silencing of p53 expression in myeloid tumors remains unknown. The loss of p53 gene expression in these cells is likely to be an important step in cancer progression and could result from cis-acting mutations within the regulatory regions of the gene or
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Figure 1
Northern transfer analysis of p53 mRNA in human myeloid leukemia cell lines. p53-positive lymphoblast cells BL-30 and LCL-4 were used as positive controls for p53 expression.
from the loss of required trans-acting factors. Our goal has been to determine whether mutational events in the p53 transcriptional regulatory regions of the gene represent a mechanism by which p53 expression is silenced.
To confirm the lack of p53 expression in cells derived from myeloid tumors, we assayed the level of p53 mRNA. Figure 1 shows a Northern transfer analysis assaying the level of p53 mRNA in a series of different myeloid leukemia-derived cell lines. As shown, the myeloid derived lines K562, U937, THP1 and KG1 do not express detectable p53 mRNA. BL-30 and LCL-4 are lymphoblast lines and HEL is derived from a human erythroleukemia. These three cell lines all express p53 mRNA. Control hybridizations for GAPDH mRNA demonstrated abundant levels of this message in these cells.
There are a number of possible explanations for the lack of expression of p53 in myeloid lines. One explanation, found to be the case in HL-60 cells, is that loss of expression is due to deletions in the gene. 4 In order to test this possibility we performed Southern transfer
Figure 2
DNA sequence and map of the human p1 p53 promoter. Known transcription factor binding sites are highlighted as is the predicted transcription initiation site. The sequences used as primers used for amplification of the promoter, as well as for DNA sequencing are also shown.
analysis to assay for the presence of an intact human p53 transcriptional regulatory region and for the presence of intact p53 coding sequences. Within the limits of resolution of these assays, the cells appear to carry an intact p53 gene and intact upstream sequences with no detectable deletions or rearrangements. Therefore, the loss of p53 expression is not due to the loss of or to major rearrangements in the gene or its regulatory sequences.
Alternatively, loss of expression may be due to base pair alterations or mutations in the p53 promoters that destroy their ability to direct proper transcription initiation. For example, mutations in transcription factor binding sites within the retinoblastoma tumor suppressor gene (Rb) have been identified and provide a mechanism for the loss of Rb expression in patients with retinoblastoma. 5 The lack of p53 transcription in the myeloid cell types described above could also be due to mutations within regulatory regions of the p53 gene.
In order to study the human p53 promoter derived from p53-null myeloid cells, an 1164-bp promoter fragment was isolated from genomic DNA by PCR amplification (see Figure 2 for map of promoter). The resulting PCR products were then cloned into the pCR2.1-TOPO vector and DNA was isolated and subjected to DNA sequencing to verify the isolate. The sequences were compared to a wild-type p53 promoter isolated from human foreskin fibroblasts, as well as the published p53 promoter (GenBank X54156) originally isolated from an SV40 transformed human fibroblast cell line, SV80. The DNA sequences were aligned and no insertions or deletions were identified. Although there were some base pair substitutions found, we believe that these are most likely nucleotide polymorphisms. This is because none of the alterations mapped to known transcription factor binding sites within the p53 promoter.
In order to assay the function of the p53 regulatory regions from p53-null cells, we cloned the promoter/transcriptional regulatory sequences into luciferase reporter vectors and tested for their transcriptional activity by transfection into the human cell lines U2OS (expresses wild-type p53) and T98G (expresses high levels of mutant p53). Vectors expressing the Renilla luciferase gene from the HSV-TK promoter were co-transfected to normalize for transfection efficiencies.
The results of these transfections indicate that the activities of the human p53 promoters isolated from the p53-null myeloid cells are comparable to the published wild-type promoter 6 (p1) and the promoter isolated from normal human fibroblasts (Figure 3) . In comparing expression to the wild-type p53 promoters, there were no significant differences in the activities of the promoters that were isolated from the different sources. We conclude from these results that the lack of TO THE EDITOR T cell large granular lymphocytic (LGL) leukemia is usually an indolent lymphoproliferative disorder which results from clonal expansion of previously activated cytotoxic T cells. 1, 2 The cells of most T-LGL leukemias express characteristic T cell differentiation antigens (ie CD3, CD8) and bear rearranged T cell receptor (TCR) beta, gamma and delta chain genes. 1 In addition, T-LGLs usually express the human natural killer (NK) marker (CD57); however, they display poor NK activity.
The association of clonal T-large granular lymphocyte proliferations (CT-LGLP) with clonal B cell lymphoproliferative disorders (CB-LPD), although rare, is now well recognized. 1, 3, 4 We present eight patients 6 Further experiments will reveal whether the lack of p53 expression in myeloid leukemias is due to aberrant epigenetic or post-transcriptional events. Case 2, a 54-year-old female, with long-standing steroid-unresponsive idiopathic thrombocytopenic purpura who had undergone splen-
